{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-022609","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2023-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.971378+00:00","generated_at":"2026-06-14T23:00:02.662012+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Achieve Life Sciences enters $16.56M contingent convertible loan facility, refinancing prior debt","bullets":["Term loan of $16.56M from Silicon Valley Bank/FCB and affiliates to refinance existing $15M contingent convertible debt.","Conversion price set at $9.34/share; mandatory conversion if stock closes at ≥$24 for 30 consecutive trading days.","Maturity Dec 22, 2024, accelerated to Aug 1, 2024 if NDA filing not accepted by July 31, 2024.","Issuer may call loan at 125% of principal before June 22, 2023, or 150% after; Lenders waived call price on prior loan.","Loan secured by substantially all assets except intellectual property; Lenders restricted from short sales."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-022609","json":"https://secwatch.observer/filing/0000950170-23-022609.json","markdown":"https://secwatch.observer/filing/0000950170-23-022609.md","text":"https://secwatch.observer/filing/0000950170-23-022609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017023022609/0000950170-23-022609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017023022609/achv-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:00:02.662012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"429f2f10a51eea937421f6dde7598e4fec140944","claim":"ACHIEVE LIFE SCIENCES, INC. incurred term loan of aggregate original principal amount of $16.56 million with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P., as lenders at floating rate per annum equal to the greater of (i) 2.25% and (ii) the prime rat maturing December 22, 2024, subject to acceleration upon failure to receive FDA filing communication by certain dates.","evidence_excerpt":"On May 15, 2023, Achieve Life Sciences, Inc. (“ Achieve ”) entered into a contingent convertible debt agreement (the “ Debt Agreement ”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“ FCB ”), in its capacity as administrative agent and collateral agent (in such capacity, the “ Agent ”), FCB, as a lender, SVB Innovation Credit Fund VIII, L.P., as a lender (“ Innovation ”), and Innovation Credit Fund VIII-A, L.P., as a lender (together with FCB and Innovation, the “ Lenders ”), pursuant to which the Lenders provided term loans having an aggregate original principal amount of $16.56 million (the “ Convertible Term Loan ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017023022609/0000950170-23-022609-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"aggregate original principal amount of $16.56 million"},{"label":"Counterparty","value":"Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P., as lenders"},{"label":"Rate","value":"floating rate per annum equal to the greater of (i) 2.25% and (ii) the prime rat"},{"label":"Maturity","value":"December 22, 2024, subject to acceleration upon failure to receive FDA filing communication by certain dates"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"56722d41bb799224a57959cd66186614787c5c4a","claim":"ACHIEVE LIFE SCIENCES, INC. entered into Debt Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and the Lenders (SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P.) valued at $16.56 million (effective 2023-05-15).","evidence_excerpt":"On May 15, 2023, Achieve Life Sciences, Inc. (“ Achieve ”) entered into a contingent convertible debt agreement (the “ Debt Agreement ”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“ FCB ”), in its capacity as administrative agent and collateral agent (in such capacity, the “ Agent ”), FCB, as a lender, SVB Innovation Credit Fund VIII, L.P., as a lender (“ Innovation ”), and Innovation Credit Fund VIII-A, L.P., as a lender (together with FCB and Innovation, the “ Lenders ”), pursuant to which the Lenders provided term loans having an aggregate original principal amount of $16.56 million (the “ Convertible Term Loan ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017023022609/0000950170-23-022609-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and the Lenders (SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P.)"},{"label":"Value","value":"$16.56 million"},{"label":"Effective","value":"2023-05-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}